Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2022-12-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于增加自有闲置资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the increase in the amount of idle funds for cash management. It details the board meeting resolution, investment purpose, investment amount, product types, risk analysis, and approval procedures. The document is a formal announcement about a financing/capital management decision, specifically about increasing the company's cash management limits and investment in low-risk financial products. It does not contain financial statements, quarterly or annual results, nor is it a transcript or a report publication notice. It is not a regulatory filing or certification. The content fits best under Capital/Financing Update (CAP) as it relates to the company's capital management and financing activities.
2022-12-30 Chinese
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the governance structure, roles, responsibilities, qualifications, nomination, election, and duties of independent directors within the company. The content focuses on internal governance rules and procedures related to board members, specifically independent directors. There is no financial data, no mention of financial results, no audit opinions, no shareholder voting results, no legal proceedings, no capital changes, no earnings announcements, and no investor presentations. The document is a governance-related policy document outlining internal rules and practices for board governance. Therefore, it fits best under the category of Governance Information (CGR). The document length is sufficient and it is not a mere announcement or certification, so it is not RPA or RNS. Confidence is high given the clear focus on governance rules for independent directors.
2022-12-30 Chinese
对外投资管理制度
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' which translates to 'External Investment Management System' and contains detailed internal rules and procedures for investment decision-making, approval authorities, and supervision within the company. It references compliance with company law, stock exchange listing rules, and company articles of association. The content is a governance and procedural manual rather than a financial report, earnings release, or announcement. It does not contain financial statements, audit opinions, or voting results. It is a detailed governance document outlining internal decision-making processes related to investments and operations. Therefore, it fits best under Governance Information (CGR). The document length is over 5,000 characters and contains substantive content, so it is not a mere announcement or regulatory filing.
2022-12-30 Chinese
关于召开2023年第一次临时股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about convening the 2023 first extraordinary general meeting of shareholders for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes information about the meeting time, location, voting procedures (both onsite and online), registration details, agenda items to be voted on, and attachments such as proxy forms and shareholder registration forms. The document does not contain financial statements or results but is focused on informing shareholders about the meeting and how to participate and vote on various proposals. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is over 5,000 characters and contains substantive meeting details, not just an announcement of a report publication. Therefore, the correct classification is AGM Information (AGM-R).
2022-12-30 Chinese
信息披露暂缓与豁免业务管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy and procedural manual regarding the management of information disclosure delays and exemptions for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It outlines rules, conditions, internal management processes, and confidentiality commitments related to information disclosure. There are no financial statements, earnings data, or regulatory filings of financial results. The document is a governance-related internal control and compliance policy rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-12-30 Chinese
关于变更公司类型、注册资本、修改公司章程并办理工商变更登记的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding changes in company type, registered capital, and amendments to the company's articles of association (company charter). It includes extensive legal and regulatory references, detailed comparisons of the articles before and after amendments, and procedural rules for shareholders' meetings and board responsibilities. The content is focused on corporate governance, company structure, and regulatory compliance related to company bylaws and shareholder rights. There is no indication that this is an annual report, earnings release, or financial statement. It is not a simple announcement of voting results or a proxy solicitation. The document is a governance-related filing detailing the company's internal rules and governance practices, which fits the category of Governance Information (CGR). The document length and detail confirm it is the actual governance document, not just an announcement or summary.
2022-12-30 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.